Improved Blood Management Improves Growth Opportunities For Haemonetics (HAE, GLOB)

The growth opportunities for the next fiscal year for Haemonetics Corporation HAE were discussed at a conference call between their chief financial officer, Chris Lindop, and the equity research firm Morgan Keegan. Morgan Keegan maintained their Outperform rating for the company, foreseeing a 10-15% EPS growth and a fair value of $65, which offers 22% upside potential. The firm believes acquisition of Global Med Technologies Inc GLOB empowered their blood management with unmatched information connectivity. They also believe that the recently launched Impact online product has boosted blood management at hospitals and management is targeting an increase in Impact accounts. Additionally, the incremented sales of plasma disposable diagnostics like OrthoPat and Teg should enhance their profit.